

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Kawakami, et al.

Group Art Unit: 1642

Serial No. : 08/417,174

Examiner: Huff, S.

Filed : April 5, 1995

For : MELANOMA ANTIGENS AND THEIR USE IN
DIAGNOSTICS AND THERAPEUTIC METHODS

RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.116

ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

Attn: Box AF

Sir:

RECEIVED
APR 14 1998
GROUP 1600

In response to the Official Action dated January 5, 1998, applicants respectfully request reconsideration in view of the following amendment and remarks.

IN THE CLAIMS

29. (amended) A pharmaceutical composition comprising an effective amount of gp100 (SEQ ID NO:27) or the peptides of claim 15 or claim 22 and a[n] pharmacologically acceptable excipient, diluent or carrier.

30. (amended) A method of treating melanoma in a mammal comprising administering a pharmaceutical composition comprising gp100 (SEQ ID NO:27) or [an immunogenic peptide fragment thereof] the peptide of claim 15 or claim 22 to said mammal in an effective amount to stimulate the production of immune cells.